• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与抗纤维蛋白Fab'结合可增强单链尿激酶型纤溶酶原激活剂的纤溶活性。

Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.

作者信息

Bode C, Runge M S, Schönermark S, Eberle T, Newell J B, Kübler W, Haber E

机构信息

Medizinische Klinik III (Kardiologie), Universität Heidelberg, FRG.

出版信息

Circulation. 1990 Jun;81(6):1974-80. doi: 10.1161/01.cir.81.6.1974.

DOI:10.1161/01.cir.81.6.1974
PMID:2111744
Abstract

Single-chain urokinase plasminogen activator (scu-PA) that had been modified with N-succinimidyl-3-(2-pyridyldithio)propionate was covalently linked by disulfide bonds to the Fab' of a monoclonal antibody specific for the beta-chain of fibrin (antibody 59D8). scu-PA-59D8 Fab' conjugate was separated from free scu-PA and two-chain urokinase coupled to 59D8 Fab' by two-step affinity chromatography. First, the reaction mixture was chromatographed on a column containing Sepharose linked to the peptide that had been used as immunogen for antibody 59D8; scu-PA-59D8 Fab' conjugate and unconjugated 59D8 Fab' were retained but not unconjugated scu-PA. Then, the eluate from the peptide-Sepharose column was chromatographed on a column containing Sepharose linked to benzamidine, which acts as a ligand for two-chain urokinase. The molecular weight of the scu-PA-59D8 Fab' conjugate was approximately 100 kDa when electrophoresed on a nonreducing sodium dodecylsulfate-polyacrylamide gel. Enzymatic assay after purification revealed that more than 97% of the scu-PA present in the conjugate retained the single-chain form. The Fab' portion of the conjugate functioned in a manner indistinguishable from that of native antibody 59D8. In an in vitro assay for lysis of fibrin monomer, the fibrinolytic potency of scu-PA-59D8 Fab' was 33-fold more than that of tissue plasminogen activator (p less than 0.001), 230-fold more than that of unconjugated scu-PA (p less than 0.0001), and 420-fold more than that of urokinase (p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

用N-琥珀酰亚胺基-3-(2-吡啶二硫基)丙酸修饰的单链尿激酶型纤溶酶原激活剂(scu-PA)通过二硫键与针对纤维蛋白β链的单克隆抗体的Fab'共价连接(抗体59D8)。通过两步亲和层析将scu-PA-59D8 Fab'缀合物与游离scu-PA以及与59D8 Fab'偶联的双链尿激酶分离。首先,将反应混合物在含有与用作抗体59D8免疫原的肽连接的琼脂糖的柱上进行层析;scu-PA-59D8 Fab'缀合物和未缀合的59D8 Fab'被保留,但未缀合的scu-PA没有。然后,将来自肽-琼脂糖柱的洗脱液在含有与苯甲脒连接的琼脂糖的柱上进行层析,苯甲脒作为双链尿激酶的配体。在非还原十二烷基硫酸钠-聚丙烯酰胺凝胶上电泳时,scu-PA-59D8 Fab'缀合物的分子量约为100 kDa。纯化后的酶活性测定表明,缀合物中存在的scu-PA超过97%保持单链形式。缀合物的Fab'部分的功能与天然抗体59D8的功能没有区别。在纤维蛋白单体溶解的体外测定中,scu-PA-59D8 Fab'的纤溶活性比组织纤溶酶原激活剂高33倍(p<0.001),比未缀合的scu-PA高230倍(p<0.0001),比尿激酶高420倍(p<0.0001)。(摘要截断于250字)

相似文献

1
Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.与抗纤维蛋白Fab'结合可增强单链尿激酶型纤溶酶原激活剂的纤溶活性。
Circulation. 1990 Jun;81(6):1974-80. doi: 10.1161/01.cir.81.6.1974.
2
Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.与抗纤维蛋白单克隆抗体结合可增强组织型纤溶酶原激活剂在体外的纤溶活性。
Biochemistry. 1988 Feb 23;27(4):1153-7. doi: 10.1021/bi00404a012.
3
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.一种由纤维蛋白片段-D-二聚体特异性人源化单克隆抗体和截短的单链尿激酶组成的重组嵌合纤溶酶原激活剂的特性分析
Eur J Biochem. 1992 Apr 1;205(1):139-46. doi: 10.1111/j.1432-1033.1992.tb16761.x.
4
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.一种由纤维蛋白片段D - 二聚体特异性人源化单克隆抗体和截短的单链尿激酶组成的重组嵌合纤溶酶原激活剂的溶栓和药代动力学特性
Thromb Haemost. 1992 Aug 3;68(2):170-9.
5
Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.一种抗体-尿激酶偶联物的特性。一种靶向纤维蛋白的纤溶酶原激活剂。
J Biol Chem. 1987 Aug 5;262(22):10819-23.
6
Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.具有增强纤维蛋白结合能力的重组嵌合纤溶酶原激活剂的特性分析
Biochim Biophys Acta. 2001 Apr 7;1546(2):399-405. doi: 10.1016/s0167-4838(01)00161-3.
7
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.通过在纤溶酶切割位点融合获得的嵌合型(组织型/尿激酶型)纤溶酶原激活剂的特性。
Thromb Haemost. 1993 May 3;69(5):466-72.
8
Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.纤维蛋白特异性抗体Fab'-尿激酶偶联物介导的溶栓作用。
J Mol Cell Cardiol. 1987 Apr;19(4):335-41. doi: 10.1016/s0022-2828(87)80578-3.
9
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.嵌合组织型和尿激酶型纤溶酶原激活剂的溶栓及药代动力学特性
Circulation. 1991 Sep;84(3):1216-34. doi: 10.1161/01.cir.84.3.1216.
10
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Blood. 1987 Feb;69(2):592-6.

引用本文的文献

1
A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.一种新型强效溶栓融合蛋白,由抗不溶性纤维蛋白抗体和突变型尿激酶组成。
Thromb Haemost. 2022 Jan;122(1):57-66. doi: 10.1055/a-1488-3723. Epub 2021 Jun 15.
2
Translational initiatives in thrombolytic therapy.溶栓治疗的转化研究。
Front Med. 2017 Mar;11(1):1-19. doi: 10.1007/s11684-017-0497-8. Epub 2017 Mar 2.
3
Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody.D-二聚体与糖蛋白IIb/IIIa单链双特异性抗体的构建与表达。
Exp Ther Med. 2013 Aug;6(2):552-556. doi: 10.3892/etm.2013.1132. Epub 2013 May 30.
4
Vascular targeting of antithrombotic agents.抗血栓药物的血管靶向作用。
IUBMB Life. 2011 Aug;63(8):632-9. doi: 10.1002/iub.474. Epub 2011 Jul 15.
5
Thrombolytics: drug interactions of clinical significance.溶栓剂:具有临床意义的药物相互作用。
Drug Saf. 2000 Nov;23(5):391-9. doi: 10.2165/00002018-200023050-00004.
6
New plasminogen activators: a clinical review.新型纤溶酶原激活剂:临床综述
Clin Cardiol. 1999 Mar;22(3):165-71. doi: 10.1002/clc.4960220303.
7
Staphylokinase as a plasminogen activator component in recombinant fusion proteins.葡萄球菌激酶作为重组融合蛋白中的纤溶酶原激活剂成分。
Appl Environ Microbiol. 1999 Feb;65(2):506-13. doi: 10.1128/AEM.65.2.506-513.1999.
8
Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Ann Hematol. 1994 Oct;69(4):S35-40. doi: 10.1007/BF02215957.
9
A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.一种对纤维蛋白具有高亲和力的重组嵌合纤溶酶原激活剂在体外和体内均具有增强的溶栓效力。
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10337-41. doi: 10.1073/pnas.88.22.10337.
10
Cardiovascular therapies in the 1990s. An overview.20世纪90年代的心血管治疗。综述。
Drugs. 1991 Mar;41(3):345-57. doi: 10.2165/00003495-199141030-00003.